Twenty-Five Years of Contemplating Genotype-Based Hereditary Hemochromatosis Population Screening
Abstract
:1. Introduction
2. Biochemical and Clinical Penetrance
3. Health Economic Aspects
4. Societal Acceptability
5. Professional Recommendations
5.1. U.S. Preventive Services Task Force (USPTF)
5.2. American Association for the Study of Liver Disease (AASLD)
5.3. European Association for the Study of the Liver (EASL)
5.4. US Centers for Disease Control and Prevention
5.5. The American College of Medical Genetics and Genomics
5.6. Others
6. To Screen, and How, or Not to Screen?
Funding
Acknowledgments
Conflicts of Interest
References
- Adams, P.C. The natural history of untreated HFE-related haemochromatosis. Acta Haematol. 2009, 122, 134–139. [Google Scholar] [CrossRef] [PubMed]
- Udani, K.; Chris-Olaiya, A.; Ohadugha, C.; Malik, A.; Sansbury, J.; Paari, D. Cardiovascular manifestationsin hospitalized patients with hemochromatosis in the United States. Int. J. Cardiol. 2021, 342, 117–124. [Google Scholar] [CrossRef] [PubMed]
- Aronow, W.S. Management of cardiac hemochromatosis. Arch. Med. Sci. 2018, 14, 560–568. [Google Scholar] [CrossRef]
- Niederau, C.; Fischer, R.; Pürschel, A.; Stremmel, W.; Häussinger, D.; Strohmeyer, G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996, 110, 1107–1119. [Google Scholar] [CrossRef] [PubMed]
- McDonnell, S.M.; Preston, B.L.; Jewell, S.A.; Barton, J.C.; Edwards, C.Q.; Adams, P.C.; Yip, R. A survey of 2851 patients with hemochromatosis: Symptoms and response to treatment. Am. J. Med. 1999, 106, 619–624. [Google Scholar] [CrossRef]
- Adams, P.C.; Barton, J.C. How I treat hemochromatosis. Blood 2010, 116, 317–326. [Google Scholar] [CrossRef]
- Feder, J.N.; Gnirke, A.; Thomas, W.; Tsuchihashi, Z.; Ruddy, D.A.; Basava, A.; Dormishian, F.; Domingo, R., Jr.; Ellis, M.C.; Fullan, A.; et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 1996, 13, 399–408. [Google Scholar] [CrossRef]
- Beutler, E.; Gelbart, T.; West, C.; Lee, P.; Adams, M.; Blackstone, R.; Pockros, P.; Kosty, M.; Venditti, C.P.; Phatak, P.D.; et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol. Dis. 1996, 22, 187–194. [Google Scholar] [CrossRef]
- The UK Haemochromatosis Consortium. A simple genetic test identifies 90% of UK patients with haemochromatosis. Gastroenterol. Hepatol. 1997, 41, 841–844. [Google Scholar]
- Le Gac, G.; Férec, C. The molecular genetics of haemochromatosis. Eur. J. Hum. Genet. 2005, 13, 1172–1185. [Google Scholar] [CrossRef]
- Steinberg, K.K.; Cogswell, M.E.; Chang, J.C.; Caudill, S.P.; McQuillan, G.M.; Bowman, B.A.; Grummer-Strawn, L.M.; Sampson, E.J.; Khoury, M.J.; Gallagher, M.L. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001, 285, 2216–2222. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Asberg, A.; Hveem, K.; Thorstensen, K.; Ellekjter, E.; Kannelønning, K.; Fjøsne, U.; Halvorsen, T.B.; Smethurst, H.B.; Sagen, E.; Bjerve, K.S. Screening for hemochromatosis: High prevalence and low morbidity in an unselected population of 65,238 persons. Scand. J. Gastroenterol. 2001, 36, 1108–1115. [Google Scholar] [PubMed]
- Kirk, L.; Bird, J.; Ramadan, S.; Samad, A.; Adebayo, G.; Lourens, W.; Williams, J. Haemochromatosis gene frequency in a control and diabetic Irish population. Ir. J. Med. Sci. 2009, 178, 39–42. [Google Scholar] [CrossRef] [PubMed]
- Valberg, L.S.; Sorbie, J.; Ludwig, J.; Pelletier, O. Serum ferritin and iron status of Canadians. Can. Med. Assoc. J. 1976, 114, 417–421. [Google Scholar]
- Skikne, B.S.; Cook, J.D. Screening test for iron overload. Am. J. Clin. Nutr. 1987, 46, 840–843. [Google Scholar] [CrossRef]
- Adams, P.C.; Reboussin, D.M.; Barton, J.C.; McLaren, C.E.; Eckfeldt, J.H.; McLaren, G.D.; Dawkins, F.W.; Acton, R.T.; Harris, E.L.; Gordeuk, V.R.; et al. Hemochromatosis and iron-overload screening in a racially diverse population. N. Engl. J. Med. 2005, 352, 1769–1778. [Google Scholar] [CrossRef]
- Phatak, P.D.; Bonkovsky, H.L.; Kowdley, K.V. Hereditary hemochromatosis: Time for targeted screening. Ann. Intern. Med. 2008, 149, 270–272. [Google Scholar] [CrossRef]
- Burke, W.; Thomson, E.; Khoury, M.J.; McDonnell, S.M.; Press, N.; Adams, P.C.; Barton, J.C.; Beutler, E.; Brittenham, G.; Buchanan, A.; et al. Hereditary hemochromatosis. Gene discovery and its implications for population-based screening. JAMA 1998, 280, 172–178. [Google Scholar] [CrossRef] [PubMed]
- Olynyk, J.K.; Cullen, D.J.; Aquilia, S.; Rossi, E.; Summerville, L.; Powell, L.W. A population-based study of the clinical expression of the hemochromatosis gene. N. Engl. J. Med. 1999, 341, 718–724. [Google Scholar] [CrossRef]
- Beutler, E.; Felitti, V.J.; Koziol, J.A.; Ho, N.J.; Gelbart, T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002, 359, 211–218. [Google Scholar] [CrossRef]
- Andersen, R.V.; Tybjærg-Hansen, A.; Appleyard, M.; Birgens, H.; Nordestgaard, B.G. Hemochromatosis mutations in the general population: Iron overload progression rate. Blood 2004, 103, 2914–2919. [Google Scholar] [CrossRef] [PubMed]
- Delatycki, M.B.; Allen, K.J.; Nisselle, A.E.; Collins, V.; Metcalfe, S.; du Sart, D.; Halliday, J.; Aitken, M.A.; Macciocca, I.; Hill, V.; et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005, 366, 314–316. [Google Scholar] [CrossRef]
- Allen, K.J.; Gurrin, L.C.; Constantine, C.C.; Osborne, N.J.; Delatycki, M.B.; Nicoll, A.J.; McLaren, C.E.; Bahlo, M.; Nisselle, A.E.; Vulpe, C.D.; et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 2008, 358, 221–230. [Google Scholar] [CrossRef] [PubMed]
- Whitlock, E.P.; Garlitz, B.A.; Harris, E.L.; Beil, T.L.; Smith, P.R. Screening for hereditary hemochromatosis: A systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2006, 145, 209–223. [Google Scholar] [CrossRef]
- U.S. Preventive Services Task Force. Screening for hemochromatosis: Recommendation statement. Ann. Intern. Med. 2006, 145, 204–208. [Google Scholar] [CrossRef]
- Grosse, S.D.; Gurrin, L.C.; Bertalli, N.A.; Allen, K.J. Clinical penetrance in hereditary hemochromatosis: Estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes. Genet. Med. 2018, 20, 383–389. [Google Scholar] [CrossRef] [PubMed]
- Willis, G.; Wimperis, J.Z.; Smith, K.C.; Fellows, I.W.; Jennings, B.A. Haemochromatosis gene C282Y homozygotes in an elderly male population. Lancet 1999, 354, 221–222. [Google Scholar] [CrossRef]
- van Aken, M.O.; De Craen, A.J.M.; Gussekloo, J.; Moghaddam, P.H.; Vandenbroucke, J.P.; Heijmans, B.T.; Slagboom, P.E.; Westendorp, R.G.J. No increase in mortality and morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old: The Leiden 85-plus Study. Eur. J. Clin. Investig. 2002, 32, 750–754. [Google Scholar] [CrossRef]
- Coppin, H.; Bensaid, M.; Fruchon, S.; Borot, N.; Blanche, H.; Roth, M.P. Longevity and carrying the C282Y mutation for haemochromatosis on the HFE gene: Case control study of 492 French centenarians. Br. Med. J. 2003, 327, 132–133. [Google Scholar] [CrossRef]
- Piippo, K.; Louhija, J.; Tilvis, R.; Kontula, K. You may live to the age of more than 100 years even if you are homozygous for a haemochromatosis gene mutation. Eur. J. Clin. Investig. 2003, 33, 830–831. [Google Scholar] [CrossRef]
- Pankow, J.S.; Boerwinkle, E.; Adams, P.C.; Guallar, E.; Leiendecker-Foster, C.; Rogowski, J.; Eckfeldt, J.H. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: The Atherosclerosis Risk in Communities (ARIC) Study. Transl. Res. 2008, 152, 3–10. [Google Scholar] [CrossRef] [PubMed]
- Adams, P.C.; Pankow, J.S.; Barton, J.C.; Acton, R.T.; Leiendecker-Foster, C.; McLaren, G.D.; Speechley, M.; Eckfeldt, J.H. HFE C282Y homozygosity is associated with lower total and low-density lipoprotein cholesterol: The hemochromatosis and iron overload screening study. Circ. Cardiovasc. Genet. 2009, 2, 34–37. [Google Scholar] [CrossRef] [Green Version]
- Demetz, E.; Tymoszuk, P.; Hilbe, R.; Volani, C.; Haschka, D.; Heim, C.; Auer, K.; Lener, D.; Zeiger, L.B.; Pfeifhofer-Obermair, C.; et al. The haemochromatosis gene Hfe and Kupffer cells control LDL cholesterol homeostasis and impact on atherosclerosis development. Eur. Heart J. 2020, 41, 3949–3959. [Google Scholar] [CrossRef] [PubMed]
- Phatak, P.D.; Guzman, G.; Woll, J.E.; Robeson, A.; Phelps, C.E. Cost-effectiveness of screening for hereditary hemochromatosis. Arch. Intern. Med. 1994, 154, 769–776. [Google Scholar] [CrossRef] [PubMed]
- Rogowski, W.H. The cost-effectiveness of screening for hereditary hemochromatosis in Germany: A remodeling study. Med. Decis. Mak. 2009, 29, 224–238. [Google Scholar] [CrossRef] [PubMed]
- de Graaff, B.; Neil, A.; Sanderson, K.; Si, L.; Yee, K.C.; Palmer, A.J. A Systematic Review and Narrative Synthesis of Health Economic Studies Conducted for Hereditary Haemochromatosis. Appl. Health Econ. Health Policy 2015, 13, 469–483. [Google Scholar] [CrossRef] [PubMed]
- Rogowski, W.H.; (University of Bremen, Bremen, Germany). Personal communication, 2022.
- de Graaff, B.; Neil, A.; Si, L.; Yee, K.C.; Sanderson, K.; Gurrin, L.; Palmer, A.J. Cost-Effectiveness of Different Population Screening Strategies for Hereditary Haemochromatosis in Australia. Appl. Health Econ. Health Policy 2017, 15, 521–534. [Google Scholar] [CrossRef]
- Hicken, B.L.; Calhoun, D.C.; Tucker, D.C. Genetic testing for hemochromatosis: Attitudes and acceptability among young and older adults. Genet. Test. 2003, 7, 235–239. [Google Scholar] [CrossRef]
- Hicken, B.L.; Calhoun, D.A.; Barton, J.C.; Tucker, D.C. Attitudes about and psychosocial outcome of HFE genotyping for hemochromatosis. Genet. Test. 2004, 8, 90–97. [Google Scholar] [CrossRef]
- Gason, A.A.; Aitken, M.A.; Metcalfe, S.A.; Allen, K.J.; Delatycki, M.B. Genetic susceptibility screening in schools: Attitudes of the school community towards hereditary haemochromatosis. Clin. Genet. 2005, 67, 166–174. [Google Scholar] [CrossRef]
- Stuhrmann, M.; Hoy, L.; Nippert, I.; Schmidtke, J. Genotype-based screening for hereditary hemochromatosis: II. Attitudes toward genetic testing and psychosocial impact—A report from a German pilot study. Genet. Test. 2005, 9, 242–254. [Google Scholar] [CrossRef]
- Power, T.E.; Adams, P.C.; Barton, J.C.; Acton, R.T.; Howe, E.; Palla, S.; Walker, A.P.; Anderson, R.; Harrison, B. Psychosocial impact of genetic testing for hemochromatosis in the HEIRS Study: A comparison of participants recruited in Canada and in the United States. Genet. Test. 2007, 11, 55–64. [Google Scholar] [CrossRef] [PubMed]
- Delatycki, M.B.; Wolthuizen, M.; Collins, V.; Varley, E.; Craven, J.; Allen, K.J.; Gurrin, L.C.; Aitken, M.; Trembath, M.K.; Bond, L.; et al. ironXS: High-school screening for hereditary haemochromatosis is acceptable and feasible. Eur. J. Hum. Genet. 2012, 20, 505–509. [Google Scholar] [CrossRef] [PubMed]
- Bacon, B.R.; Adams, P.C.; Kowdley, K.V.; Powell, L.W.; Tavill, A.S. American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54, 328–343. [Google Scholar] [CrossRef] [PubMed]
- European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J. Hepatol. 2010, 53, 3–22. [Google Scholar] [CrossRef]
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on haemochromatosis. J. Hepatol. 2022, 77, 479–502. [Google Scholar] [CrossRef]
- Waalen, J.; Beutler, E. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 2008, 358, 2293–2294; Author reply 2294–2295. [Google Scholar] [PubMed]
- CDC. Available online: https://www.cdc.gov/genomics/resources/diseases/hemochromatosis.htm (accessed on 24 August 2022).
- Miller, D.T.; Lee, K.; Abul-Husn, N.S.; Amendola, L.M.; Brothers, K.; Chung, W.K.; Gollob, M.H.; Gordon, A.S.; Harrison, S.M.; Hershberger, R.E.; et al. ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 2022, 24, 1407–1414. [Google Scholar] [CrossRef]
- Laberge, A.M. Recommending inclusion of HFE C282Y homozygotes in the ACMG actionable gene list: Cop-out or stealth move toward population screening? Genet. Med. 2018, 20, 400–402. [Google Scholar] [CrossRef]
- Nussbaum, R.L.; Haverfield, E.; Esplin, E.D.; Aradhya, S. Response to “The use of ACMG secondary findings recommendations for general population screening: A policy statement of the American College of Medical Genetics and Genomics (ACMG)”. Genet. Med. 2019, 21, 2836–2837. [Google Scholar] [CrossRef]
- WHO. Screening Programmes: A Short Guide. Increase Effectiveness, Maximize Benefits and Minimize Harm. Available online: https://apps.who.int/iris/bitstream/handle/10665/330829/9789289054782-eng.pdf (accessed on 24 August 2022).
- Wilson, J.; Jungner, G. Principles and Practice of Screening for Disease; World Health Organization: Geneva, Switzerland, 1968; Available online: https://apps.who.int/iris/bitstream/handle/10665/37650/.WHO_PHP_34.pdf?sequence=17 (accessed on 24 August 2022).
- Krawczak, M.; Cooper, D.N.; Schmidtke, J. Estimating the efficacy and efficiency of cascade genetic screening. Am. J. Hum. Genet. 2001, 69, 361–370. [Google Scholar] [CrossRef] [PubMed]
- Rhodes, D.A.; Raha-Chowdhury, R.; Cox, T.M.; Trowsdale, J. Homozygosity for the predominant Cys282Tyr mutation and absence of disease expression in hereditary haemochromatosis. J. Med. Genet. 1997, 34, 761–764. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Service-Public: Examen de Prevention en Santé. Available online: https://www.service-public.fr/particuliers/vosdroits/F170?lang=en (accessed on 24 August 2022).
- Bundesgesundheitsministerium: Gesundheits-Check-Up. Available online: https://www.bundesgesundheitsministerium.de/checkup.html (accessed on 24 August 2022).
- NHS Health Check. Available online: https://www.nhs.uk/conditions/nhs-health-check/ (accessed on 24 August 2022).
- Victoria State Government Department of Health: Regular Health Checks. Available online: https://www.betterhealth.vic.gov.au/health/servicesandsupport/regular-health-checks (accessed on 24 August 2022).
- Pilling, L.C.; Tamosauskaite, J.; Jones, G.; Wood, A.R.; Jones, L.; Kuo, C.-L.; Kuchel, G.A.; Ferrucci, L.; Melzer, D. Common conditions associated with hereditary haemochromatosis genetic variants: Cohort study in UK Biobank. BMJ 2019, 364, k5222, Erratum in BMJ 2019, 367, l6157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Schmidtke, J. Twenty-Five Years of Contemplating Genotype-Based Hereditary Hemochromatosis Population Screening. Genes 2022, 13, 1622. https://doi.org/10.3390/genes13091622
Schmidtke J. Twenty-Five Years of Contemplating Genotype-Based Hereditary Hemochromatosis Population Screening. Genes. 2022; 13(9):1622. https://doi.org/10.3390/genes13091622
Chicago/Turabian StyleSchmidtke, Jörg. 2022. "Twenty-Five Years of Contemplating Genotype-Based Hereditary Hemochromatosis Population Screening" Genes 13, no. 9: 1622. https://doi.org/10.3390/genes13091622
APA StyleSchmidtke, J. (2022). Twenty-Five Years of Contemplating Genotype-Based Hereditary Hemochromatosis Population Screening. Genes, 13(9), 1622. https://doi.org/10.3390/genes13091622